Antiviral Activity of Trappin-2 and Elafin In Vitro and In Vivo against Genital Herpes

Anna G. Drannik,a Kakon Naga,b Jean-Michel Sallenave,c–d,e Kenneth L. Rosenthalfg,h

Department of Medicine, Neurology Division, McMaster University, Hamilton, Ontario, Canadaa; Department of Biomolecular Engineering, Nagatsuta-cho, Midori-ku, Tokyo Institute of Technology, Yokohama, Japanb; Unité de Défense Innée et Inflammation, Institut Pasteure, Paris, Francec; Unité U874 INSERM, Paris, Franced; Université Paris Diderot, Sorbonne Paris Cité (Cellule Pasteur), Paris, Francee; McMaster Immunology Research Centre,f Michael G. DeGrootef Institute for Infectious Disease Research,g and Department of Pathology & Molecular Medicine,h McMaster University, Hamilton, Ontario, Canada

Serine protease inhibitor elafin (E) and its precursor, trappin-2 (Tr), have been associated with mucosal resistance to HIV-1 infection. We recently showed that Tr/E are among principal anti-HIV-1 molecules in cervicovaginal lavage (CVL) fluid, that E is ~130 times more potent than Tr against HIV-1, and that Tr/E inhibited HIV-1 attachment and transcytosis across human genital epithelial cells (ECs). Since herpes simplex virus 2 (HSV-2) is a major sexually transmitted infection and risk factor for HIV-1 infection and transmission, we assessed Tr/E contribution to defense against HSV-2. Our in vitro studies demonstrated that pretreatment of endometrial (HEC-1A) and endocervical (End1/E6E7) ECs with human Tr-expressing adenovirus (Ad/Tr) or recombinant Tr/E proteins before or after HSV-2 infection resulted in significantly reduced virus titers compared to those of controls. Interestingly, E was ~7 times more potent against HSV-2 infection than Tr. Conversely, knockdown of endogenous Tr/E by small interfering RNA (siRNA) significantly increased HSV-2 replication in genital ECs. Recombinant Tr and E reduced viral attachment to genital ECs by acting indirectly on cells. Further, lower viral replication was associated with reduced secretion of proinflammatory interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-α) and decreased NF-κB nuclear translocation. Additionally, protected Ad/Tr-treated ECs demonstrated enhanced interferon regulatory factor 3 (IRF3) nuclear translocation and increased antiviral IFN-β in response to HSV-2. Lastly, in vivo studies of intravaginal HSV-2 infection in Tr-transgenic mice (Etg) showed that despite similar virus replication in the genital tract, Etg mice had reduced viral load and TNF-α in the central nervous system compared to controls. Collectively, this is the first experimental evidence highlighting anti-HSV-2 activity of Tr/E in female genital mucosa.

The estimated seroprevalence of herpes simplex virus 2 (HSV-2) in North America is nearly 20% and is even higher, around 30 to 80%, in some developing countries and sub-Saharan Africa (1, 2). These numbers make genital herpes one of the leading and most prevalent sexually transmitted infections (STIs) worldwide. Most sexual and perinatal transmissions of HSV-2 occur during asymptomatic, or “mute,” mucocutaneous viral shedding (3), when a person is unaware of transmitting the pathogen to others. More alarming is the fact that HSV-2 is closely linked to HIV-1 infections, by being a risk factor for HIV-1 acquisition (4) and transmission (5, 6).

As a natural consequence of attachment, entry, and infection, viruses, including HSV-2, become exposed to a variety of innate sensors, or pathogen recognition receptors (PRRs), including Toll-like receptors (TLRs), RNA helicases, and inflammasomes (7, 8). Subsequently, viral recognition triggers a series of intracellular signal transduction events that activate key transcription factors involved in antiviral and inflammatory responses. Specifically, upon activation, mitogen-activated protein kinase (MAPK), NF-κB (9), and the interferon (IFN) regulatory factors (IRF) (10) coordinate the expression of genes with antiviral and inflammatory activity. Type I IFNs (11), with IFN-β leading the way in defense against HSV-2 (12, 13), and interferon-stimulated genes (ISGs) (14, 15) are only a few examples of factors contributing to antiviral defense.

Exposure to HSV-2 also triggers the release of proinflammatory mediators, including tumor necrosis factor alpha (TNF-α) (16), interleukin 1β (IL-1β), and IL-6 (9, 12). Such factors contribute not only to the induction of protective innate and adaptive immune responses (12, 17) but also, if poorly controlled, to the development of systemic inflammatory reactions, as seen in neonatal sepsis (18), or in breaching the blood-brain barrier and HSV translocating into the central nervous system (CNS) (16, 19). HSV-2 enters the nervous system through the sensory nerve fibers within the stratified squamous epithelium into the dorsal root ganglion. Following the episode of acute infection, HSV-2 establishes a lifelong and latent infection, arguably in sensory ganglia, with recurrent episodes of reactivation and symptomatic or asymptomatic viral shedding at the original sites of viral entrance at the dermal and mucosal surfaces (20). These processes, however, remain poorly understood in humans. While HSV-2 infection in humans is not usually life-threatening, unless generalized, murine models demonstrate high morbidity and mortality associated with viral CNS dissemination, limb paralysis, and extensive mucosal and skin lesions, often requiring animal euthanasia (16). Hence, a murine model of HSV-2 infection may not be the most appropriate to mimic HSV-2 in humans. Regardless of the severity and presentation of herpetic lesions, the “mute” transmission of HSV-2, its lifelong latency, and the interplay between genital herpes and HIV-1 infections (21) place HSV-2 among high-priority targets for vaccine development.
infections, requiring the development of novel and efficient therapeutic and preventative measures, especially those protecting the genital mucosal.

Human genital epithelial cells (ECs), being the principle target in HSV-2 infection, respond to viral encounter by releasing innate antimicrobial factors in efforts to eradicate or contain viral replication (22, 23). Serine protease inhibitor elafin (E) and its precursor, trappin-2 (Tr), along with secretory leukocyte protease inhibitor (SLPI) and defensins, belong to a large family of cationic antimicrobials that have been linked to endogenous mucosal protection against sexually transmitted pathogens, including HSV-2 and HIV-1 (23–26). Trappin-2 and elafin (Tr/E), as well as SLPI, share the cysteine-rich fold with four disulfide bonds called the whey acidic protein (WAP) domain, involved in protease inhibition (27). Secreted as unglycosylated protein, Tr (9.9 kDa) (28) (or pre- or full-length elafin) contains an N-terminal cementoin domain (38 amino acids [aa]) (29), and elafin (5.9 kDa) contains a C-terminal 57-residue domain with a WAP structure (30, 31).

Inhibition of human neutrophil elastase and proteinase 3 through the WAP domain allows Tr/E to control excessive inflammation and tissue damage. Additionally, cross-linking between the transglutaminase-binding motifs located on the N terminus of each Tr/E (29, 32) and extracellular matrix proteins like heparin and fibronectin makes Tr/E indispensable for repairing compromised tissue integrity (33).

Both Tr and E have also been shown to possess broad-spectrum antibacterial (34) and antifungal properties (32). Furthermore, and others have shown that Tr/E exert immunomodulatory activity, where depending on the environment, they can either dampen inflammation or promote immunostimulatory events and prime the immune system (35–37). Tr/E are found at mucosal surfaces and in secretions, including cervicovaginal lavage fluid (CVL) (22, 23, 38); in tissues, like skin, placenta, and genital and gastrointestinal tracts (38–44); and in multiple cell types, such as neutrophils, macrophages, keratinocytes, and epithelial cells (12, 22, 45), including genital ECs (22, 38). Tr/E are regarded as alarm antiproteases, since they are produced mainly in response to proinflammatory stimuli, such as lipopolysaccharide (LPS) (46), TNF-α (47), and IL-1β (38, 48). Additionally, Tr/E were recently shown to be induced and secreted by genital ECs in response to poly(I:C), a surrogate of a viral double-stranded RNA (dsRNA) (22, 35, 49), thus further supporting their importance in the inflammatory environment.

We and others recently demonstrated the importance of Tr/E in increased antiviral protection against HIV-1 as well as enhanced poly(I:C)-induced antiviral immune responses (22, 23, 30, 35, 49). Specifically, elevated Tr/E levels in CVLs of HIV-exposed seronegative commercial sex workers (CSWs) were found to be associated with mucosal HIV-1 resistance (23) and to significantly contribute to CVL’s natural anti-HIV-1 activity in vitro (49). However, the contribution of Tr/E to defense against HSV-2 genital infections remains undefined. The objective of this study was to elucidate whether and how each Tr/E individually contributes to anti-HSV-2 defense mechanisms in female genital mucosa.

### MATERIALS AND METHODS

#### Reagents

Two commercial Tr and E proteins were tested following protein reconstitution as per the manufacturer’s instruction: (i) human recombinant 6xHis-Tr (with a C terminus His tag) (R&D Systems, Burlington, ON, Canada) (35, 49); (ii) commercial human recombinant E (without a tag) HC4011 (Hyctul Biotech, Uden, Netherlands) (49). Poly(I:C) (P1530; Sigma-Aldrich, Oakville, ON, Canada) was reconstituted in the phosphate-buffered saline (PBS).

#### Cell lines and viruses

Human endometrial carcinoma 1A (HEC-1A; ATCC HTB-112; Rockville, MD) and Vero African green monkey kidney cells (ATCC CCL81) were maintained in McCoy’s 5A modified medium (Invitrogen Life Technologies, Burlington, ON, Canada) and in alpha minimal essential medium (α-MEM) (Invitrogen Life Technologies), correspondingly, supplemented with 10% fetal bovine serum, 1% HEPES, 1% l-glutamine (Invitrogen Life Technologies), and 1% penicillin-streptomycin (Sigma-Aldrich, Oakville, ON, Canada). The endocervical End1/E6E7 cell line (kind gift from M. Fichorova, Brigham & Women’s Hospital, Boston, MA) was generated as described before (50) and maintained in keratinocyte serum-free medium ( Gibco/BRL; Life Technologies) supplemented with 50 μg/ml bovine pituitary extract, 0.1 ng/ml epidermal growth factor, 100 units/ml penicillin, 100 μg/ml streptomycin, and CaCl2 to a final calcium concentration of 0.4 mM. All cell were cultured at 37°C in 5% CO2. Stocks of HSV-2 (strain 333) were generated using Vero cells and stored at −70°C until used.

#### HSV-2 in vitro model

For viral infections, ECs were first pretreated with Tr/E for 1 h in serum-free medium, followed by HSV-2 inoculum in the same serum-free medium for an additional 2 h, after which virus was removed, cells were repeatedly washed with PBS, and complete growth medium was added for 24 or 48 h. In some experiments, Tr and E proteins were added not before but rather 2 h after HSV-2 infection and cell washings. To this end, HEC-1A cells were incubated with Tr/E for 1 h at 37°C in a serum-free medium, to which a complete growth medium was subsequently added for 24 h. After the infection, supernatants were collected and stored cell free at −70°C until further use. Viral titers were determined by plaque assay using Vero cells grown on 12-well plates to 70 to 80% confluence. Virus-containing samples were serially diluted in serum-free medium and added to Vero cell monolayers. Infected monolayers were incubated at 37°C for 2 h, being rocked every 15 min for viral adsorption, and subsequently overlaid with complete α-MEM culture medium further supplemented with 0.05% human immune serum globulin (Canadian Blood Services). Infection was allowed to occur for 48 h at 37°C. Monolayers were then fixed and stained with crystal violet, and viral plaques were counted under a light microscope and expressed as PFU per milliliter of HSV-2.

#### Adenoviral constructs and their delivery into cell culture

The replication-deficient adenoviral constructs (Ad) used in this study have been described in detail elsewhere (35, 51–53). To express human Tr, the Ad/Tr vector, encoding a gene for 95-aa human Tr, was used (52, 53). This adenoviral construct was previously called Ad/E. E1,E3-deleted empty adenovirus Ad-dl703 (Ad/dl), coding for no transgene, was used as a control for Ad/Tr (51). Both Ad vectors were prepared at the Centre for Gene Therapeutics at McMaster University (Hamilton, ON, Canada). ECs were either treated with Opti-MEM I reduced serum medium (Invitrogen Life Technologies) alone (untreated [UT]) or with a multiplicity of infection (MOI) of 50 PFU of Ad/dl or Ad/Tr at 37°C overnight. After repeated PBS washes and rest for 4 h, cells were exposed to various MOIs of HSV-2 in a serum-free medium for 2 h and then repeatedly washed with PBS, and complete growth medium was added for an additional 24 to 48 h. Viral titers were determined in cell-free supernatants as described above, pertaining to cell lines and viruses.

#### Viral attachment

Viral attachment was determined as described previously (24), but with slight modifications. Briefly, cells and virus were first pretreated with either medium or Tr/E for 1 h at 37°C. Cells pretreated with medium received either virus alone or virus pretreated with proteins for 1 h at 37°C. Cells that were pretreated with proteins first were either repeatedly washed or not and exposed to HSV-2 virus with an MOI of 1 (1 PFU per 1 cell) for 5 h at 4°C to allow for viral attachment. After repeated washes with PBS to remove unbound virus, cell-associated virus was detected by probing Western blots (WB) of whole-cell lysates with...
anti-gD primary antibody (P1103; Virusys, Atlanta, GA) and anti-GAPDH antibody (ab9485; Abcam) to control for protein loading.

**MTT viability assay.** MTT [3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide] assay (Biotium Inc., Hayward, CA) was used as per the manufacturer’s instruction to determine viability of HEC-1A cells after Ad and HSV-2 exposure and was described elsewhere (13, 35).

**Tr/E knockdown by RNA interference.** A small interfering RNA (siRNA) molecule (Invitrogen Life Technologies) was used to target human Tr/E (GenBank accession number NM_002638) within positions 67 to 420 with a single open reading frame (ORF) through the following nucleotide sequence, starting from Tr/E gene position 202: 5\'-GCCGGGA AAAAGGCAAAGUUU-3\'. RNA interference (RNAi) negative control (medium GC content), catalog no. 12935-300 (Invitrogen Life Technologies), was used as a nontargeting siRNA control. Reverse and scaled-down for a 96-well plate, transfections of siRNA control. Reverse and scaled-down for a 96-well plate, transfections of siRNA (8 pmol) were done using Lipofectamine RNAiMAX and Opti-MEM medium (Invitrogen Life Technologies) as per the supplier’s instructions. HEC-1A cells, 3 × 10^5 in a 100-μl total volume of complete growth medium, were transfected in a 96-well BD Falcon culture plate (BD Biosciences) for 48 to 72 h before challenging with HSV-2 at an MOI of 0.1 and 1. Knockdown efficiency was monitored by assessing Tr/E content in supernatants of HEC-1A cells using Tr/E enzyme-linked immunosorbent assay (ELISA) 24 h after viral challenge.

**ELISAs.** Cell-free samples were stored at −70°C until assayed for human Tr/E, IL-8, IL-6, and TNF-α with an ELISA Duoset kit (R&D Systems) and for human IFN-β by an ELISA kit from Antigenic America Inc. (Huntington Station, NY), according to the supplier’s protocol. For animal experiments, murine TNF-α, IL-6, MIP-2, and IFN-γ levels were measured using ELISA Duoset kits (R&D Systems), and for IFN-β detection, ELISA was conducted using the PBL biomedical kit from PBL (Piscataway, NJ). Analytes were quantified based on standard curves obtained using a Tecan Safire ELISA reader (MTX Labs Systems Inc.) as per the supplier’s protocol.

**Preparation of cell extracts and WB analysis.** Whole-cell extracts were prepared by using whole-cell extract buffer (50 mM Tris-HCl [pH 8.0], 130 mM NaCl, 1% NP-40, 1% SDS, and 1× protease inhibitor [Roche, Mississauga, ON, Canada]) as per standard protocol. Protein amount was quantified using a Bradford assay with bovine serum albumin (Sigma-Aldrich) as a standard and Bio-Rad dye reagent concentrate as a protein stain (Bio-Rad Laboratories, Mississauga, ON, Canada). WB was performed on a 10% polyacrylamide denaturing SDS-PAGE gel and polyvinylidene difluoride (PVDF) membranes (Amersham, Arlington Heights, IL) as per standard protocol, using anti-gD primary antibody (P1103; Virusys, Atlanta, GA) and anti-GAPDH primary antibody (ab9485; Abcam) to control for protein loading. After incubation with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibody (Bio-Rad Laboratories), blots were visualized using a SuperSignal West Femto or Pico chemiluminescent substrate kit (Thermo Scientific, Rockford, IL). Quantification of band intensities was done using MBF Imagej for Microscopy Software.

**Immunofluorescence staining.** Immunofluorescence staining was performed as described before, but with minor modifications. HEC-1A cells grown on an 8-well BD Falcon culture slide (BD Biosciences) were pretreated with Tr and E proteins for 1 h before receiving either medium or HSV-2 at an MOI of 1 per well for 4 h. Following treatment, cells were fixed and blocked as described elsewhere (13, 14). IRF3 was detected using a 1:100 dilution (in blocking solution) of primary antibody IBL18781 (IBL, Gunma, Japan) for 1 h; NF-κB p65 sc-372 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:500) was used to detect nuclear translocation of NF-κB p65; gD was detected using anti-gD primary antibody (1:100) (P1103; Virusys, Atlanta, GA). Negative-control rabbit immunoglobulin fraction (DakoCytomation, Glostrup, Denmark) served as an isotype control and was diluted to match the protein content of the primary antibodies. Secondary antibodies, Alexa Fluor 488-conjugated goat anti-rabbit IgG, Alexa Fluor 488-conjugated goat anti-mouse, and Alexa Fluor 647-conjugated goat anti-rabbit antibodies (Molecular Probes, Eugene, OR), were added to cells in a blocking solution for 1 h. Nuclei were visualized by staining with propidium iodide. Images were acquired using an inverted laser-scanning confocal microscope (LSM 510; Zeiss, Oberkochen, Germany).

**RNA extraction and real-time quantitative PCR analysis.** The protocol for RNA isolation was described elsewhere (35, 54). Briefly, total RNA was isolated from infected HEC-1A cells and HSV-2 for 6 h, using TRIzol reagent (Invitrogen Life Technologies), and DNase treated (Ambion, Austin, TX), as per the supplier’s recommendations. RNA was quantified using the Agilent 2100 Bio-Analyzer (Agilent, Santa Clara, CA). Total RNA was reverse transcribed into cDNA with SuperScript reverse transcriptase III (Invitrogen Life Technologies). Real-time quantitative PCR was performed in a total volume of 25 μl using 1× universal PCR master mix (Applied Biosystems, Foster City, CA), 5 μl of diluted cDNA, 500 nmol forward primer, 500 nmol reverse primer (Mobix; McMaster University, ON, Canada), and 200 nmol probe in a 96-well plate. TaqMan oligonucleotide primers and probes, listed below and labeled with 6-carboxyfluorescein (FAM) at the 5′ end and a nonfluorescent quencher at the 3′ end, were designed using Primer Express 1.5 and purchased from Applied Biosystems: IFN-β, 5′-GGCggga GTGacACTA-3′ (forward) and 5′-CCgagggtCTCTCAacAAAatA GTA-3′ (reverse); 18S RNA, 5′-cggattaCTACgAcAATCTgCt CA-3′ (probe), 5′-GTgacTAgGCGCTTCTgATgT-3′ (forward), and 5′-TGCCAgAGTGGTGCTTTAT-3′ (reverse). The expression of 18S ribosomal RNA was used as an internal control. PCR was run with the standard program: 95°C for 10 min and 40 times of cycling at 95°C for 15 s and 60°C for 1 min in a 96-well plate with an ABI PRISM 7900HT sequence detection system using Sequence Detector Software 2.2 (Applied Biosystems).

**Animals.** Female mice used in this study included wild-type (WT) C57BL/6 mice (Charles River Canada, St. Constant, Quebec, Canada) and EcDNA mice, also on a C57BL/6 background, that were generated to express the gene for human full-length elafin (pre-elafin), or trappin-2, under the MCMV promoter as described elsewhere (55). Presence of the Tr gene was routinely confirmed with genotypic analysis as per standard protocol. All mice were 8 to 16 weeks old and maintained in level B housing conditions in a 12-hour light-dark cycle. All experimental protocols involving mice were approved by the Animal Research Ethics Board of McMaster University.

**HSV-2 in vivo model.** Five days before viral challenge, mice were injected subcutaneously with 2 mg of Depo-Provera (Depo) (Upjohn, Don Mills, ON, Canada) to facilitate vaginal infection, since Depo is a long-acting progesterone formulation that induces a diestrus-like state in the genital tract. Mice were anesthetized with ketamine (150 mg/kg) and xylazine (10 mg/kg) and injected intraperitoneally (i.p.), their tails were lifted, and 1 × 10^3 PFU/mouse was administered intravaginally (IVAG) in a total volume of 10 μl in PBS. Mice were kept on their backs under the influence of anesthesia between 45 min and 1 h to allow the inoculum to be retained. Mice were monitored daily for survival and disease progression using the following five-point scale: 0, no apparent inflammation and infection; 1, slight redness of external vaginal os; 2, swelling and redness of external vaginal os; 3, severe swelling and redness of both vaginal os and surrounding tissue and hair loss in genital area; 4, genital ulceration with severe redness, swelling, and hair loss of genital and surrounding tissue; 5, severe genital ulceration extending to surrounding tissue or signs of paralysis. Animals were euthanized at stage 5. Vaginal washes were collected daily over 8 days by pipetting twice consecutively with 30 μl of PBS in and out of the vagina of unanesthetized mice several times. On days 2, 6, and 8 postinoculation, whole genital tracts as well as spinal cords and brain-stems were removed, placed in 1 ml of PBS, and processed individually via homogenization as described earlier (56). Viral titers were determined in supernatants using plaque assay as described earlier in this section.

**Statistical analysis.** Statistical analysis was performed with either nonpaired Student’s t test for differences between two groups or a one-
way analysis of variance (ANOVA) for more than two groups, using Sigma Stat 2.0. Survival curves were compared with a log rank test using GraphPad Prism version 4.0. In all cases, data were expressed as means ± standard deviations (SD), and P values of <0.05 were considered significant.

RESULTS

Tr/E significantly reduce HSV-2 replication in genital ECs. To elucidate if and how Tr/E contribute to defense against HSV-2 challenge in genital ECs, the role of exogenous Tr/E proteins was assessed. A replication-deficient adenovirus construct expressing the human Tr gene (Ad/Tr) (35, 52, 53) was used to express human Tr in endometrial HEC-1A and endocervical End1/E6E7 EC lines. To elucidate whether each Tr/E individually exhibits anti-HSV-2 activity, as well as to counteract side effects of adenovirus-expressed Tr, we also utilized recombinant Tr and E with HEC-1A cells. Figure 1A shows that supernatants from HEC-1A cells infected with Ad/Tr (Ad/Tr cells), prior to HSV-2 infection, had significantly (P < 0.05) lower HSV-2 titers than HEC-1A cells infected with a control Ad/dl vector (51) (Ad/dl cells). Although viral load in Ad/dl cells alone appeared to be reduced compared to untreated (UT) cells, the reduction in HSV-2 shedding in Ad/Tr cells was significantly greater, indicating that exogenous Tr further reduced viral replication and augmented anti-HSV-2 protection in ECs. A similar inhibitory pattern of Tr on HSV-2 replication was also demonstrated in endocervical End/E6E7 ECs (Fig. 1B), albeit it was not as marked as in HEC-1A cells. To determine if each Tr/E exhibits anti-HSV-2 activity, recombinant Tr/E (rTr/E) proteins were used to pretreat HEC-1A cells. Data in Fig. 1C and D demonstrate that each rTr/E independently significantly (P < 0.05) reduced viral titers in HEC-1A cells, compared to medium alone. The inhibition of HSV-2 replication was dose dependent and with physiologically relevant (0.04 to 1 μg/ml) protein concentrations for the female genital tract (22). Additionally, we ruled out impaired cell viability as a potential cause of reduced susceptibility to viral infection by performing an MTT viability assay (data not shown). Taken together, our results demonstrate that Tr and E, each individually, in physiologic concentrations not toxic to cells, have the capacity to inhibit HSV-2 replication and enhance antiviral protection.

E has greater anti-HSV-2 activity than Tr. We next determined the comparative potency of each Tr/E against HSV-2 by identifying the 50% inhibitory concentration (IC50) values of Tr/E, given that tested recombinant Tr/E proteins possessed similar antiprotease activity (49). The IC50s for Tr/E with respect to infectivity of HEC-1A cells were estimated to be 0.07 ± 0.01 μg/ml and 0.01 ± 0.008 μg/ml (Fig. 1E). Comparison of IC50s for each Tr/E revealed that anti-HSV-2 efficacy of E was about 7 times greater than for Tr. Collectively, these results revealed that E is superior to its precursor, Tr, with respect to anti-HSV-2 activity.

Knockdown of endogenous Tr/E by siRNA significantly increased HSV-2 replication in HEC-1A cells. To corroborate results shown in Fig. 1, endogenous Tr/E were knocked down in HEC-1A cells by Tr/E-specific small interfering RNA (siRNA), and cells were subsequently challenged with HSV-2. Figure 2A shows that levels of secreted Tr/E detected by ELISA in HEC-1A cell supernatants were significantly (P < 0.05) reduced after Tr/E siRNA knockdown and HSV-2 treatment, compared to those of control siRNA- and HSV-2-treated cells. Interestingly, the levels of Tr/E in the siRNA control group appeared to be moderately induced by HSV-2 challenge compared to medium-treated cells.

The stimulatory effect, however, was more pronounced with the lower viral MOI challenge, and Tr/E expression was even completely abrogated following the high viral challenge (MOI of 5) (data not shown), suggesting a regulatory mechanism exploited by HSV-2 against antimicrobial innate factors. Further, cells that received Tr/E-specific siRNA and were challenged with HSV-2 had significantly increased amounts of infectious virus detected in supernatants (P = 0.02) compared to control siRNA-treated cells that maintained their endogenous Tr/E production and were better protected against HSV-2 challenge at an MOI of 0.1 (Fig. 2B). However, this protection in control siRNA-treated cells was overcome when a higher dose of HSV-2, an MOI of 1, was used (P < 0.01), which could be a consequence of viral downregulatory mechanisms against Tr/E. All siRNA-untreated cells had Tr/E levels within

FIG 1 Tr and E reduce HSV-2 replication in genital ECs, and E has greater anti-HSV-2 activity than Tr. Genital ECs were left untreated (UT) or treated with an MOI of 0 to 50 of Ad/dl or Ad/Tr and inoculated with HSV-2 at an MOI of 0.1 to 5. Viral titers in supernatants were determined 24 h postinfection by standard plaque assay and presented as log-transformed PFU/ml for HEC-1A cells (A) and for End1/E6E7 (B). In panels C and D, HEC-1A cells were pretreated with Tr (C) and E (D) for 1 h and subsequently exposed to HSV-2 at an MOI of 1 for 2 h and, after repeated washes, cultured for an additional 24 h. Viral titers were determined in supernatants by plaque assay. For all, the data are shown as the means ± SD and are representative of three independent experiments performed in triplicate. Statistical analysis was performed using Student’s t test (A, B) or ANOVA with Tukey’s post hoc test (C, D), with significance indicated in graphs. For determining IC50s of Tr and E anti-HSV-2 activity, readouts from dose-dependent functional studies were used for determining efficiency parameters of relevant experimental points. The maximum inhibitory effect was considered 100% effect, and the other values were computed accordingly and plotted against relevant doses of Tr (*) and E (○) as percentages of maximal inhibitory effect. (E) The relevant IC50s for Tr and E are indicated with a filled arrowhead and an open arrowhead, respectively, pertaining to inhibitory effects of Tr and E on HSV-2 infectivity of HEC-1A cells. Error bars, SD.
positively), repeatedly washed, and exposed to HSV-2, reduced were first pretreated with Tr or E (Fig. 3C, lane 4 or 6, respectively) and then added onto cells, similarly reduced amounts of gD were detected. Figure 3B and D show quantifying histograms of corresponding bands depicted in Fig. 3A and C. Notably, the inhibitory effect of E (Fig. 3A, lanes 7 and 8, and C, lanes 5 and 6) was more pronounced compared to the effect of Tr (Fig. 3A, lanes 5 and 6, and C, lanes 3 and 4). Interestingly, though, in separate repeated experiments using African green monkey kidney epithelial (Vero) cells, a preincubation of HSV-2 or cells with recombinant Tr and E did not have any inhibitory effect on viral infection of Vero cells (Fig. 3E and F), suggesting that Tr and E did not act directly on HSV-2 but rather on cells. Further, these results also suggested a selective antiviral mechanism of Tr and E in the female human genital ECs, compared to in African green monkey kidney ECs. Finally, since we earlier demonstrated that anti-HIV-1 activity of Tr/E was associated with nuclear localization (31), we next tested if Tr/E could act against HSV-2 beyond binding/attachment, by adding the proteins to HEC-1A cells 2 h after viral infection, as described in Materials and Methods. Figure 3G shows that both Tr and E were able to significantly reduce viral replication in HEC-1A cells even when added after viral infection, indicating that they can also act at the postentry level. Collectively, these results clearly indicate that Tr and E inhibited HSV-2 at the entry and postentry levels, and this was associated with reduced viral attachment to genital ECs, which was mediated through indirect interaction of Tr and E with the cells.

Ad/Tr cells respond to HSV-2 challenge with increased IFN-β secretion. The protective role of IFN-β against HSV-2 infection is well established (12–14, 58). We determined whether Tr/E pretreatment of genital ECs could increase IFN-β expression in response to HSV-2 challenge. Figure 4A shows that mRNA levels of IFN-β in Ad/Tr cells were significantly (P = 0.007) increased at 6 h after low-dose HSV-2 challenge of HEC-1A cells, compared to those in Ad/dl control cells. Further, the stimulatory effect was also evident from ELISA data, showing significantly (P = 0.039) increased levels of IFN-β protein in supernatants of Ad/Tr cells compared to those in Ad/dl controls at 24 h postinfection (Fig. 4B). Overall, these data indicate that genital ECs exposed to Ad-expressed Tr before HSV-2 challenge secrete higher levels of IFN-β upon HSV-2 exposure.

Tr/E-treated ECs exhibit increased HSV-2-induced nuclear translocation of IRF3. Interferon regulatory factor 3 (IRF3) is one of the key factors contributing to poly(I:C)-induced antiviral protection via activation of ISGs either with or without the induction of IFN-β (14, 35, 59, 60). Here, we determined whether Ad/Tr cells, with reduced viral load and induced IFN-β secretion, would exhibit increased nuclear translocation of IRF3 following HSV-2 challenge. Immunofluorescence staining for IRF3 nuclear translocation demonstrates that in the presence of medium alone, adenovirus-un-treated HEC-1A cells (UT), or Ad/dl and Ad/Tr cells did not have significant translocation of IRF3 (green) into the nucleus (red), as no merged (yellow) color was present within the nucleus (Fig. 4C and D). In contrast, in HSV-2-treated rows, for both an MOI of 1 and 5, Ad/Tr cells showed a markedly increased number of cells with IRF3 nuclear translocation compared to control cells (Fig. 4C). Additionally, HEC-1A cells pretreated with recombinant Tr/E proteins also showed enhanced IRF3 nuclear translocation (Fig. 4D, white arrows), compared to virus-only-treated cells (Fig. 4D, HSV-2 MOI 1). Interestingly, Tr/E-treated cells with nuclear IRF3 also demonstrated the presence of HSV-2
gD in the cytoplasm, indicating that increased IRF3 nuclear translocation in these cells was not a result of reduced viral exposure, given that viruses are known to downregulate IRF3 activation. Taken together, these results indicate that preexposure of HEC-1A cells to either Ad-expressed Tr or recombinant Tr/E proteins enhanced nuclear translocation of IRF3 that was also associated with increased anti-HSV-2 protection of cells.

Tr/E-treated ECs secrete significantly reduced HSV-2-induced proinflammatory cytokines. A physiologically relevant outcome of the attachment, entry, and infection of cells with HSV-2 is the release of immune-inflammatory factors (9, 12, 16), which may contribute to the pathogenesis and inflammation associated with genital herpes (61, 62). Given that Tr/E were previously shown to exert anti-inflammatory effects against bacterial (63, 64) and viral (30, 35, 49) ligands, we next determined whether pretreatment of genital ECs with Tr/E affected HSV-2-induced levels of proinflammatory IL-8 and TNF-α. Figure 5 shows that Ad/Tr cells (Fig. 5A) or HEC-1A cells pretreated with 1 μg/ml of each recombinant Tr/E before viral challenge (Fig. 5B and C) responded to HSV-2 infection with significantly (P < 0.05) reduced levels of IL-8 and TNF-α at 24 h, compared to the Ad/dl or medium-only groups, respectively. The secreted TNF-α in Ad-treated
cell supernatants, however, was below the ELISA detection level (data not shown). All together, these data demonstrate that exogenous Tr/E modulated the secretion of inflammatory factors by ECs in response to HSV-2 challenge, which was also associated with reduced viral replication and attachment to cells.

**Tr/E-treated ECs exhibit reduced HSV-2-triggered NF-κB nuclear translocation.** NF-κB is one of the key transcription factors that regulate production of antiviral and proinflammatory factors, like IL-8 and TNF-α, upon encounter with viral ligands (9, 65), and Tr/E were previously shown to reduce NF-κB activation in response to bacterial (66) and viral ligand stimulation (35). Thus, given the reduced secretion of IL-8 and TNF-α observed in this study, we next determined if Tr/E pretreatment of HEC-1A cells results in attenuated NF-κB activation after HSV-2 exposure.

Immunofluorescence staining was performed, assessing the localization of the p65 subunit of NF-κB (green) in HEC-1A cells, with nuclei visualized with propidium iodide (red), HSV-2 gD (blue), and composite (yellow) at magnifications of ×2520 or ×1260 (D, left column). The data are representative of two independent experiments with similar results.
Although some nuclear localization of p65 was noted in Ad/Tr- and Tr/E-treated and virus-exposed groups, the intensity of the observed signal was substantially reduced compared to that of virus-only- or Ad/dl-HSV-2-treated groups (Fig. 5E and F). This reduction in nuclear NF-κB staining in Tr/E-treated virus-exposed groups was not due to a lack of virus exposure, since gD staining was observed (Fig. 5F). Collectively, these data indicate that pretreatment with both Tr and E before viral challenge reduces HSV-2-triggered nuclear translocation of the p65 subunit of NF-κB, which was also associated with reduced secretion of proinflammatory IL-8 and TNF-α. Next, we elucidated whether attenuated NF-κB activity in Tr/E-pretreated cells was associated with altered levels of innate sensors TLR3, RIG-I, and MDA-5, since we recently showed them to be modulated in the presence of Tr/E in response to poly(I·C) (35) and HIV-1 stimulation (31). However, no changes between the groups were detected (data not shown), suggesting a differential mechanism of Tr/E antiviral activity with different viral pathogens.

**Tr-transgenic (Etg) mice** have significantly lower viral load and reduced TNF-α protein levels in the CNS following intra-vaginal HSV-2 challenge compared to control mice. Considering our *in vitro* findings in human genital ECs, next we tested antiviral
properties of Tr in a murine model of genital HSV-2 infection. Since mice do not produce Tr/E, Tr-transgenic mice (earlier referred to as the full-length-elnfin-transgenic mice, thus the name Etg) (55) were used, along with their corresponding wild-type (WT) C57BL/6 counterparts. Mice were intravaginally inoculated with a lethal 1 × 10^6 PFU per mouse of wild-type HSV-2 strain 333. Viral titers determined by plaque assay in vaginal washes (A) and in supernatants of homogenized genital tracts (GT) (B) and spinal cord with brainstem (SC+BS) (C), as well as protein levels of TNF-α determined by ELISA in supernatants of GT and SC+BS (D), pathology score (E), and survival (F) are shown. For survival and disease score, cumulative data (n = 30 to 34 mice) are presented. For viral titers and TNF-α levels, the representative data are from three independent experiments (n = 3 or 4 mice per group, per time point) and are shown as the means ± SD. Statistical analyses of survival curves were performed with a log rank test using GraphPad Prism. Statistical analyses of disease scores, viral titers, and TNF-α levels were performed using Student’s t test, with significance indicated in graphs.

FIG 6 Tr-transgenic (Etg) mice have significantly lower viral load and reduced TNF-α protein levels in the CNS compared to control mice. Wild-type (WT) control mice or transgenic mice expressing the gene for human Tr (Etg) were Depo treated and 5 days later intravaginally inoculated with 1 × 10^6 PFU per mouse of wild-type HSV-2 strain 333. Viral titers determined by plaque assay in vaginal washes (A) and in supernatants of homogenized genital tracts (GT) (B) and spinal cord with brainstem (SC+BS) (C), as well as protein levels of TNF-α determined by ELISA in supernatants of GT and SC+BS (D), pathology score (E), and survival (F) are shown. For survival and disease score, cumulative data (n = 30 to 34 mice) are presented. For viral titers and TNF-α levels, the representative data are from three independent experiments (n = 3 or 4 mice per group, per time point) and are shown as the means ± SD. Statistical analyses of survival curves were performed with a log rank test using GraphPad Prism. Statistical analyses of disease scores, viral titers, and TNF-α levels were performed using Student’s t test, with significance indicated in graphs.

DISCUSSION

High prevalence of HSV-2 infection (45, 67), its serious complications in neonates and immunocompromised individuals (68), and the close interplay with HIV-1 (5) are worrisome and continue to remind us of the lack of efficient control of this STI. Identification of novel molecules capable of controlling primary HSV-2 infection and inflammatory responses at mucosal sites may advance our efforts in designing effective measures to curb both HSV-2 and HIV-1 infections.

We evaluated the contribution of each Tr/E to host defense against HSV-2 by utilizing human genital ECs in vitro and a model of genital HSV-2 infection in Tr-transgenic mice in vivo. Our results demonstrated that Tr/E likely influenced HSV-2 infection by acting indirectly on cells, rather than through virus, and targeting viral attachment and potentially postentry cellular antiviral and inflammatory responses, although the precise mechanism remains unknown. Cells pretreated with Tr/E secreted significantly lower levels of proinflammatory factors IL-8 and TNF-α and had attenuated nuclear translocation of NF-kB following HSV-2 challenge, which was not due to the lack of viral exposure or reduced viral attachment. Moreover, reduced viral replication in Tr/E-treated cells was also associated with increased IFN-β secretion and nuclear translocation of IRF3; the latter, once again, was not associated with reduced viral exposure of HEC-1A cells. Interestingly, we found that recombinant E was more potent against HSV-2 infection than its precursor, Tr. Finally, our results from in vivo experiments showed that Tr-transgenic mice, compared to WT controls, showed a consistent trend of increased survival; and a better disease outcome was also associated with lower viral translocation from the GT into the CNS, as well as reduced levels of TNF-α at the target organs. Collectively, these observations likely describe multiple antiviral activities of Tr/E in defense against HSV-2 infection in the female genital mucosa.

Although it is unclear at the moment how specifically Tr/E inhibited viral attachment to HEC-1A cells, our results propose that Tr/E may act through the target cells. Despite that we and
others have recently demonstrated direct antiviral activities of Tr/E against vesicular stomatitis virus (VSV) (35) as well as HIV-1 (22, 31, 49), our findings could indicate that in defense against HSV-2, Tr/E acts indirectly through cells but not through the virus. Considering that Tr/E can bind to heparin and fibronectin (33), the interaction between Tr/E and cell surface HSV-2 binding/entry receptors, including heparan sulfate (HS) chains and nectin-1 and nectin-2 members of the immunoglobulin superfamily (57), can be one of the proposed modes of Tr/E antiviral activity. This suggested mechanism could explain why we observed decreased viral titers and attachment of HSV-2 to HEC-1A cells that resemble primary genital ECs and highly express HS moieties (69). An indirect inhibitory anti-HSV-2 effect of SLPI would support our data, since SLPI was found to exert its protective antiviral effect by interacting through ECs and not virus (70). However, the involvement of annexin II in anti-HSV-2 defense, which was important for anti-HIV-1 activity of SLPI, was ruled out (25). The observed inhibitory effect of Tr/E on HSV-2 attachment may have significant implications, since viral attachment to ECs is one of the critical steps required for subsequent fusion and entry of HSV-2 into ECs. Thus, our results indicate that Tr/E may affect the pathogenesis of HSV-2 by interfering with viral entry and consequently the establishment of primary HSV-2 infection mucosally, as well as by hindering entry/access and spread of virus in the nervous system.

Sensing of endogenous Tr/E with siRNA further corroborated the importance of Tr/E in anti-HSV-2 defense in the genital ECs. Our results also showed that the inhibitory effect of endogenous Tr/E was overcome with higher viral inoculum, suggesting a context-dependent nature of anti-HSV-2 activity of endogenous Tr/E that can be limited by HSV-2 evasion mechanisms. One such evasion mechanism may involve the regulation of Tr/E production, since we found significantly reduced mRNA and protein levels of Tr/E in cells challenged with a high dose (MOI of 5) of HSV-2 (data not shown), in contrast to a somewhat stimulatory effect from the low-dose viral challenge (Fig. 2A), as well as from the stimulation of genital ECs with a mimic of viral dsRNA, poly(I:C) (22, 35). The specific mechanisms of either stimulatory or inhibitory effects remain undefined at the moment but clearly reflect the complex dialogue between the innate immune system of the host and the pathogen.

Interestingly, a similar downregulatory evasion strategy was described for the papillomavirus protein E6 and Tr expression (71), as well as for HSV-2 and SLPI expression due to viral early-gene expression (47) and for HSV-2 and type I IFNs due to the expression of the HSV-2 virion host shutoff (Vhs) protein (58, 72). The latter two studies support our earlier findings showing that Vhs, in a dose-dependent way, inhibited innate immune sensing, IRF3 activation, and IFN-β expression in human vaginal ECs (73). All together, these data indicate that Tr/E appear to be important in the host’s defense against HSV-2, and these molecules could represent a vulnerable target of the viral evasion mechanisms that should be taken into consideration when designing protective measures against STIs.

In this study, E appeared ~7 times more potent against HSV-2 than its precursor, Tr. Interestingly, we reported a similar observation of E being more potent (~100 times) than Tr against HIV-1 (49). These findings are also in line with the earlier-mentioned report on a divergent anti-HSV-2 effect of defensins (24). It is unclear at the moment why E was more potent than Tr against HSV-2 infection. However, our data likely reflect the result of elafin’s greater ability to inhibit viral binding/entry and replication, to enter the nucleus, as well as to attenuate NF-κB phosphorylation/nuclear translocation and to modulate gene and protein expression of proinflammatory mediators.

Here, we found that IL-8 and TNF-α, as well as NF-κB nuclear translocation, were significantly diminished following exposure to each Ad/Tr and rTr/E, indicating that Tr/E can moderate HSV-2-induced antiviral immune-inflammatory responses that are also associated with decreased viral replication. We speculate, and our data would support this notion, that the observed moderation of inflammatory responses could be a result of Tr/E acting not only at the entry level, by reducing the number of attached virions, but also at the postentry level, or intracellularly, perhaps directly (DNA binding) or indirectly (upstream) targeting NF-κB transcriptional activity, all of which remain to be elucidated. The potential intracellular mechanism would be supported by earlier reports showing Tr/E-mediated reduction in LPS-induced AP-1 and NF-κB by targeting the ubiquitin-proteosome pathway (63) and upregulating IkBα (66). Moreover, the study demonstrating that SLPI can bind to DNA and compete for NF-κB binding sites, thus preventing NF-κB activation (74), and our recent finding of the dependence of anti-HIV-1 and immunomodulatory activity of Tr/E on its intranuclear localization (31) would also support the proposed intracellular mode of anti-HSV-2 action of Tr/E. Collectively, these observations may support DNA binding by Tr/E as one plausible mechanism of Tr/E antiviral activity that would explain both our reduced viral titers as well as anti-inflammatory mediators, which might be worth focusing on in future investigations.

In support of the argument that antimicrobial factors can act at multiple levels, α-defensin 1 was shown, in the absence of serum, to act directly on HIV-1 but, in the presence of serum, to inhibit HIV-1 replication by interfering with PKC phosphorylation in primary CD4 T cells (75). Interestingly, the latter report is similar to an earlier study by McMichael et al. showing that, in serum-containing conditions, Tr/E had an inhibitory effect on LPS-induced release of TNF-α (36). However, the same study reported that in serum-free conditions and at higher concentrations, Tr/E had a stimulatory activity on TNF-α release.

Recently, we demonstrated that in HEC-1A cells, following adenoviral augmentation of Tr/E and in response to poly(I:C), the secretion of inflammatory factors and the expression of innate viral sensors RIG-I and MDA5 (35) were reduced. We also showed that genital ECs, pretreated with recombinant Tr and E proteins, secreted reduced levels of proinflammatory IL-8 as well as demonstrated attenuated mRNA expression of innate viral sensors TLR3 and RIG-1 in response to R5-tropic HIV-1 (31). In contrast, no changes in expression levels of PRRs were found in this study following HSV-2 challenge (data not shown), suggesting that reduced levels of proinflammatory factors and NF-κB nuclear translocation observed here cannot be accounted for by the modulatory effect of Tr/E on PRR expression. These findings could also indicate that Tr/E could modulate immune responses toward various pathogens through differential mechanisms.

IRF3 has been shown to mediate antiviral protection through the activation of ISGs that may or may not depend on the induction of IFN-β (76, 77). Thus, it is likely that increased antiviral protection observed in Tr/E-treated and HSV-2-exposed cells was due in part to increased IRF3 nuclear translocation and conse-
quently augmented IFN-β induction. However, other IRFs, including IRF7 and IRF9, could also contribute, since IRF3 was shown to act in homo- and heterodimers (78). Overall, this is the first report of Tr/E-mediated increased IFN-β secretion and IRF3 nuclear translocation in the context of a viral infection that is also linked with increased antiviral protection of genital ECs against HSV-2 challenge. These observations clearly indicate a potential interaction between Tr/E and the IRF3 pathway, perhaps by acting through the upstream regulators of IRF3 induction. Taking into account that viruses, including HSV-2 and HIV-1, specifically target and disrupt functional activity of IRF3 as part of their evasion strategy (73, 79), such interaction might be of importance in future applications of antiviral properties of Tr/E.

A protective role of innate and adaptive immune responses mediated by NK cells, CD4+ and CD8+ cells, IL-15, and IFN-β (12, 80) has been well characterized and established in murine models of HSV-2 genital infection. However, a beneficial role of restricted antiviral and inflammatory responses was also recently highlighted (16, 81). In vivo experiments using a murine transgenic model of lethal HSV-2 intravaginal infection showed that Etg mice, expressing human Tr, had reduced viral replication in the CNS, which could be attributed to a better containment and less efficient viral translocation/spread from the local target organ, GT, into the CNS. It is unclear at the moment why viral clearance was not affected in the GT of Etg mice, as would be expected based on our in vitro data. However, this lack of antiviral protection in the GT could be related to the experimental conditions of high HSV-2 inoculum and a progesterone-driven system. Arguably, these conditions could be dampening specifically antiviral activity of Tr but sparing its immunomodulatory effects, as would be supported by decreased levels of TNF-α in GT and CNS in the Etg group. These findings could imply that Tr-mediated protection is perhaps conditional and could be overwhelmed by a higher viral load or other parameters of the infection, which was also seen in our siRNA experiments.

It is also unclear why viral translocation into the CNS was initially delayed or reduced in Etg animals at day 2, despite similar viral load in the GT. However, the sustained lower HSV-2 replication in the CNS of Etg mice is likely related to lower TNF-α levels in the GT and CNS, thus suggesting that immunomodulatory effects might be less conducive to viral systemic dissemination and might be better for a disease outcome. Our results are in line with studies demonstrating that mice lacking RNase L or with neutralized TNF-α had a better disease outcome and reduced mortality with genital HSV-2 infection (16, 81), hence confirming the beneficial role of Tr-mediated lower inflammation and viral translocation in genital HSV-2 infection. However, that only a trend of increased survival and a modest improvement in disease presentation were observed in Etg mice is a limiting factor in interpreting the significance of our observations and their extrapolations on human studies.

Although this is not the first study using Etg animals against viral challenge (37, 82), it is the first report pertaining to HSV-2 infection. Nevertheless, our study shares key observations with earlier publications. Despite the differential experimental designs and suggested antiviral mechanisms of Tr, our findings of increased antiviral protection and reduced mortality are in agreement with Zaidi et al. (acute model of viral myocarditis) (82) and Rogharian et al. (a model of adenoviral lung challenge assessing adaptive immunity) (37). That beneficial effects of Tr/E were observed in such distinct models attests to the existence of differential mechanisms of Tr/E antiviral protection that could be attributed to the pleiotropic nature of the molecules as well as the target organ specificity. Taken together, our results from in vivo studies provide evidence indicating the existence of a protective and contextual anti-HSV-2 effect of Tr/E.

In conclusion, this is the first study showing a Tr/E anti-HSV-2 effect in vitro and in vivo. This study presented novel evidence of multifactorial and complex activities of Tr/E that targeted virus-cell interaction and attachment/entry as well as mounting of antiviral and inflammatory cellular responses to HSV-2. These observations importantly complement and expand previously shown antibacterial and anti-HIV-1 activities of Tr/E and may translate into a broader use of Tr/E as microbicides in the female genital mucosa.

ACKNOWLEDGMENTS

We thank Ficherova for kindly providing End1/E6E7 cells for our experiments. We appreciate the expert and valuable technical support of J. Newton and A. Patrick.

This work was supported by a grant as part of the Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC), a key component of the Collaboration for AIDS Vaccine Development (CAVD) funded by the Bill & Melinda Gates Foundation. A.G.D. was supported by a Studentship Award from the Ontario HIV Treatment Network (OHTN) and K.L.R. by a Career Scientist Award from the OHTN.

REFERENCES

Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44:15610–15618.


